Senti Biosciences Files Definitive Proxy Statement
Ticker: SNTI · Form: DEF 14A · Filed: Jan 27, 2025 · CIK: 1854270
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, governance
TL;DR
Senti Bio filed its proxy statement for shareholder votes. Standard procedure.
AI Summary
Senti Biosciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 27, 2025, for the fiscal year ending December 31, 2024. The filing concerns the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company, previously known as Dynamics Special Purpose Corp., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing is a standard regulatory requirement for public companies, informing shareholders about upcoming meetings and voting procedures, which is crucial for corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- Dynamics Special Purpose Corp. (company) — Former company name
- 20250127 (date) — Filing date
- 20250306 (date) — Period of report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for an upcoming shareholder meeting, detailing matters to be voted upon.
When was this DEF 14A filed by Senti Biosciences, Inc.?
This DEF 14A was filed on January 27, 2025.
What is Senti Biosciences, Inc.'s fiscal year end?
Senti Biosciences, Inc.'s fiscal year ends on December 31.
What was Senti Biosciences, Inc. previously named?
Senti Biosciences, Inc. was previously named Dynamics Special Purpose Corp. until March 31, 2021, and also operated under the name Senti Biosciences, Inc. after a name change on June 15, 2022.
In which state is Senti Biosciences, Inc. incorporated?
Senti Biosciences, Inc. is incorporated in Delaware (DE).
Filing Stats: 4,878 words · 20 min read · ~16 pages · Grade level 10.9 · Accepted 2025-01-27 07:30:33
Key Financial Figures
- $0 — y's outstanding common stock, par value $0.0001, or the Common Stock, in accordanc
- $0.0001 — Convertible Preferred Stock, par value $0.0001 per share, or the Series A Preferred St
- $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
- $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
Filing Documents
- ny20041388x2_def14a.htm (DEF 14A) — 883KB
- logo_sentibio.jpg (GRAPHIC) — 33KB
- ny20041388x2_pc01.jpg (GRAPHIC) — 826KB
- ny20041388x2_pc02.jpg (GRAPHIC) — 412KB
- 0001140361-25-001942.txt ( ) — 2632KB
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 22
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 28 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 35 PRINCIPAL STOCKHOLDERS 39 HOUSEHOLDING 42 STOCKHOLDER PROPOSALS 42 OTHER MATTERS 42 ANNUAL REPORT 42 WHERE YOU CAN FIND ADDITIONAL INFORMATION 42 APPENDIX A: SENTI BIOSCIENCES, INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN A-1 TABLE OF CONTENTS SENTI BIOSCIENCES, INC. 2 Corporate Drive, First Floor South San Francisco, CA, 94080 PROXY STATEMENT FOR THE 2025 SPECIAL MEETING OF STOCKHOLDERS TO BE HELD MARCH 6, 2025 This proxy statement contains information about the 2025 Special Meeting of Stockholders, or the Special Meeting, of Senti Biosciences, Inc., which will be held on March 6, 2025 at 9:00 a.m. Pacific Time. The Special Meeting will be held virtually. You may attend the Special Meeting virtually via the Internet at www.virtualshareholdermeeting.com/SNTI2025SM, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the proxy card being mailed to you separately in order to attend the Special Meeting. The Board of Directors of Senti Biosciences, Inc. is using this proxy statement to solicit proxies for use at the Special Meeting. In this proxy statement, the terms "Senti," "Senti Biosciences," the "Company," "we," "us," and "our" refer to Senti Biosciences, Inc. The mailing address of our principal executive offices is Senti Biosciences, Inc., 2 Corporate Drive, First Floor, South San Francisco, CA, 94080. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our Board of Directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice t